Investigating the impact of dietary compounds on cognitive decline in older adults with diabetes
Systemic and dietary advanced glycation end products in type 2 diabetes-related cognitive decline and incident dementia: effects on Alzheimer's pathology and cerebrovascular disease
This study is looking at how certain foods and substances in the blood, called Advanced Glycation End products (AGEs), might affect memory and thinking skills in older adults with type 2 diabetes, to see if reducing these levels could help prevent dementia.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Rutgers Biomedical and Health Sciences NIH-funded |
| Lab location | 1 site (Newark, UNITED STATES) |
| Project ID | NIH-10889801 on NIH RePORTER |
What this research studies
This research focuses on understanding how dietary and serum levels of Advanced Glycation End products (AGEs) affect cognitive decline and Alzheimer's disease in older adults with type 2 diabetes. By enrolling 921 community-dwelling older adults, the study will assess their dietary intake and serum levels of AGEs, while also conducting annual cognitive testing to track changes over time. The goal is to determine if there is a link between high levels of AGEs and cognitive impairment, which could lead to new treatment strategies for preventing dementia in this vulnerable population.
Who could benefit from this research
Good fit: Ideal candidates for this research are older adults aged 65 and above who have been diagnosed with type 2 diabetes and are currently not experiencing dementia.
Not a fit: Patients who are younger than 65 or do not have type 2 diabetes may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to dietary recommendations or interventions that help prevent cognitive decline and dementia in older adults with type 2 diabetes.
How similar studies have performed: Previous smaller studies have suggested a connection between AGEs and cognitive decline, but this research aims to provide larger-scale evidence to support these findings.
Where this research is happening
Newark, UNITED STATES
- Rutgers Biomedical and Health Sciences — Newark, United States (Active)
Researchers
- Principal investigator: Schnaider Beeri, Michal — Rutgers Biomedical and Health Sciences
- Study coordinator: Schnaider Beeri, Michal
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.